Navigation Links
Cell Therapeutics Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval

SEATTLE, June 14, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it met with the U.S. Food and Drug Administration's (the "FDA") Division of Oncology Drug Products (the "DODP").  The meeting provided a pathway for re-submitting CTI's New Drug Application (the "NDA") for pixantrone for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") including the potential for accelerated approval based on the PIX301 study results. This meeting follows CTI's receipt of the FDA's Office of New Drugs' (the "OND") response to CTI's appeal as announced on May 3, 2011, which allows CTI the opportunity to resubmit the NDA. On appeal, the FDA recommended the Company conduct an additional review of radiographs utilizing a new independent panel of radiologists to confirm the response and progression events noted in the pixantrone NDA. The DODP meeting also focused on the documents CTI proposed to provide regarding the circumstances of stopping the enrollment of the clinical trial prior to achieving the original planned patient accrual and the make-up of the new radiology expert panel. CTI also plans to address items noted in the FDA's Complete Response Letter. The DODP confirmed that the NDA would be reviewed within six months from the resubmission of the NDA. CTI anticipates filing the additional information later this year, and could obtain FDA approval in the first half of 2012.

"We are pleased to have the opportunity to meet with the review team from the DODP and to get their feedback on what will be required for a resubmission of our pixantrone NDA. We now have a pathway to move forward with resubmitting the NDA for potential accelerated approval of pixantrone in patients with multiple relapsed or refractory aggressive NHL, which is a stage of this disease for which there are no approved agents," stated Jack W. Singer, M.D., Chief Medical Officer of CTI. "We are excited to have been given this rare second opportunity for review of the NDA and we have made this resubmission our top priority."

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the European Medicines Agency, that accelerated approval by the FDA of pixantrone may not be possible or occur, that CTI may not be able to address satisfactorily the two key matters raised by the OND or other matters raised by the DODP, the OND and/or the FDA, that CTI's interpretation of the guidance provided by the OND and/or the DODP may be different than the intent of the OND and/or the DODP, that the OND and/or the DODP may change its guidance, that the PIX301 study may not be deemed successful, that upon a re-review of the NDA the FDA may find pixantrone to not be safe and/or effective, that the PIX301 study may still be deemed to be a failed study, that the FDA may require an additional clinical trial of pixantrone, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI may not be able to provide satisfactory information in response to the FDA's Complete Response Letter, that CTI may not be able to re-submit the pixantrone NDA quickly, that CTI may not be able to fill the additional information for the NDA later this year, that CTI may not obtain approval of the NDA from the FDA in the first half of 2012, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434

Medical Information Contact:
T: 800.715.0944

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
2. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
3. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
4. Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China
5. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
6. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
7. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
8. Echo Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference
9. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
10. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
11. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... NEW YORK , November 25, 2015 ... global market of self-monitoring blood glucose devices was valued ... to grow with a CAGR of 5.7% during 2015 ... increasing geriatric population and increasing prevalence of diabetes. In ... about diabetes care is also contributing to the growth ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Complex (TSC), as well as raising public awareness of the disorder while helping ... a third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted ... to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ ... of time the doctor uses other traditional cutting tools, such as the scalpel and ...
Breaking Medicine News(10 mins):